GANTRISIN
LOE ApproachingNDAORALTABLET
Approved
Jul 1948
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 22h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
GANTRISIN is a vintage oral small-molecule antibiotic tablet approved by Roche in 1948, representing one of the earliest sulfonamide therapeutics. The exact indications and mechanism of action are not specified in available data, but historical sulfonamides were used for bacterial infections including urinary tract infections and some systemic infections. This is a legacy product now approaching loss of exclusivity.
LOE Approaching
This legacy asset faces imminent generic competition with minimal linked job opportunities, indicating a small, maintenance-focused team with limited growth trajectory.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on GANTRISIN offers minimal career advancement given zero linked job openings and LOE-approaching lifecycle status. This role suits candidates seeking stable, low-pressure legacy product management or those in late-stage portfolio rundown functions.
Regulatory Affairs SpecialistProduct Manager (Legacy/Maintenance)
Worked on GANTRISIN at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.